For the quarter ending 2026-03-31, BTAI had -$19,043K decrease in cash & cash equivalents over the period. $31,596K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|
| Net loss | 44,661 | -30,911 | -26,441 |
| Depreciation | -168 | 75 | 151 |
| Accretion of debt discount and amortization of financing costs | -681 | 440 | 743 |
| Change in fair value of derivative liabilities | 6,838 | -12,541 | 7,222 |
| Stock-based compensation expense | -1,882 | 581 | 1,736 |
| Payable-in-kind interest on credit agreement | -5,434 | 1 | 5,433 |
| Accrued interest | - | 0 | 0 |
| Operating lease right-of-use assets | -186 | 82 | 160 |
| Accounts receivable | 114 | -17 | -114 |
| Inventory | -2 | -47 | -173 |
| Prepaid expenses and other current assets | 1,232 | 480 | -673 |
| Accounts payable, accrued expenses, due to related parties, and other current liabilities | 3,254 | -1,084 | 45 |
| Operating lease liabilities | 214 | -96 | -183 |
| Net cash used in operating activities | 31,596 | -18,787 | -24,618 |
| Purchases of equipment and leasehold improvements | 0 | 0 | 0 |
| Net cash from investing activities | 0 | 0 | 0 |
| Proceeds from issuance of common stock and warrants | -43,882 | 38,234 | 14,146 |
| Payment of principal of long-term debt | 8,108 | - | - |
| Offering costs for common stock and warrants issuance | -1,334 | 686 | 806 |
| Payment of employee tax obligations related to vesting restricted stock units | -17 | 16 | 1 |
| Net cash provided by financing activities | -50,639 | 37,532 | 13,339 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -19,043 | 18,745 | -11,279 |
| Cash, cash equivalents and restricted cash, beginning of the period | 37,320 | 29,854 | - |
| Cash and cash equivalents, end of the period | 17,180 | 37,320 | - |
BioXcel Therapeutics, Inc. (BTAI)
BioXcel Therapeutics, Inc. (BTAI)